| 1 | MAP2K1, MAP2K2
|
| ERK1/2 can feedback-regulate cellular MEK1/2 levels.
|
| Hong SK, Wu PK, Karkhanis M, Park JI.
|
| Cell Signal 27(10):1939-48. doi: 10.1016/j.cellsig.2015.07.003. Epub 2015 Jul 9.
2015
|
| 2 | MAP2K1, MAP2K2, PAK1
|
| p21-activated kinase 1 (PAK1) can promote ERK activation in a kinase-independent manner.
|
| Wang Z, Fu M, Wang L, Liu J, Li Y, Brakebusch C, Mei Q.
|
| J Biol Chem 288(27):20093-9. doi: 10.1074/jbc.M112.426023. Epub 2013 May 7.
2013
|
| 3 | MAP2K2, RRM2B
|
| MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2.
|
| Piao C, Youn CK, Jin M, Yoon SP, Chang IY, Lee JH, You HJ.
|
| Cell Cycle 11(17):3237-49. doi: 10.4161/cc.21591. Epub 2012 Aug 16.
2012
|
| 4 | MAP2K1, MAP2K2
|
| Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
|
| Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, Harshman K, Guipponi M, Bukach O, Zoete V, Michielin O, Muehlethaler K, Speiser D, Beckmann JS, Xenarios I, Halazonetis TD, Jongeneel CV, Stevenson BJ, Antonarakis SE.
|
| Nat Genet 44(2):133-9. doi: 10.1038/ng.1026.
2011
|
| 5 | DLG1, MAP2K2
|
| The MEK2-binding tumor suppressor hDlg is recruited by E-cadherin to the midbody ring.
|
| Gaudet S, Langlois MJ, Lue RA, Rivard N, Viel A.
|
| BMC Cell Biol 12:55. doi: 10.1186/1471-2121-12-55.
2011
|
| 6 | MAP2K1, MAP2K2
|
| MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells.
|
| Lee CS, Dykema KJ, Hawkins DM, Cherba DM, Webb CP, Furge KA, Duesbery NS.
|
| PLoS One 6(2):e17165. doi: 10.1371/journal.pone.0017165.
2011
|
| 7 | CFC4, MAP2K2
|
| Cardiofaciocutaneous syndrome in a mother and two sons with a MEK2 mutation.
|
| Linden HC, Price SM.
|
| Clin Dysmorphol 20(2):86-8. doi: 10.1097/MCD.0b013e32833ff29d. No abstract available.
2011
|
| 8 | CFC4, MAP2K2
|
| Molecular and functional analysis of a novel MEK2 mutation in cardio-facio-cutaneous syndrome: transmission through four generations.
|
| Rauen KA, Tidyman WE, Estep AL, Sampath S, Peltier HM, Bale SJ, Lacassie Y.
|
| Am J Med Genet A 152A(4):807-14.PMID: 20358587 2010
|
| 9 | CFC, CFC3, CFC4, MAP2K1, MAP2K2
|
| Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.
|
| Dentici ML, Sarkozy A, Pantaleoni F, Carta C, Lepri F, Ferese R, Cordeddu V, Martinelli S, Briuglia S, Digilio MC, Zampino G, Tartaglia M, Dallapiccola B.
|
| Eur J Hum Genet 17(6):733-40. Epub 2009 Jan 21. 2009
|
| 10 | MAP2K1, MAP2K2
|
| Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal.
|
| Catalanotti F, Reyes G, Jesenberger V, Galabova-Kovacs G, de Matos Simoes R, Carugo O, Baccarini M.
|
| Nat Struct Mol Biol 16(3):294-303. Epub 2009 Feb 15.
2009
|
| 11 | HRAS, KRAS, BRAF, CFC2, COSTS, CFC3, MAP2K1, MAP2K2, CFC4, CFC5
|
| Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
|
| Schulz AL, Albrecht B, Arici C, van der Burgt I, Buske A, Gillessen-Kaesbach G, Heller R, Horn D, HŸbner CA, Korenke GC, Kšnig R, Kress W, KrŸger G, Meinecke P, MŸcke J, Plecko B, Rossier E, Schinzel A, Schulze A, Seemanova E, Seidel H, Spranger S, Tuysuz B, Uhrig S, Wieczorek D, Kutsche K, Zenker M.
|
| Clin Genet 73(1):62-70. Epub 2007 Nov 27. 2008
|
| 12 | MAP2K1, MAP2K2, BRAF, CFC3, CFC4, CFC2
|
| Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
|
| Senawong T, Phuchareon J, Ohara O, McCormick F, Rauen KA, Tetsu O.
|
| Hum Mol Genet 17(3):419-30. Epub 2007 Nov 2. 2008
|
| 13 | BRAF, CFC2, CFC3, CFC4, CFC5, COSTS, HRAS, KRAS, MAP2K1, MAP2K2, NS3
|
| The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
|
| Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y.
|
| Hum Mutat 29(8):992-1006.
2008
|
| 14 | CFC3, CFC4, CFC5, KRAS, MAP2K1, MAP2K2, NS3, NS5, RAF1
|
| Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.
|
| Nyström AM, Ekvall S, Berglund E, Björkqvist M, Braathen G, Duchen K, Enell H, Holmberg E, Holmlund U, Olsson-Engman M, Annerén G, Bondeson ML.
|
| J Med Genet 45(8):500-6. Epub 2008 May 2.
2008
|
| 15 | CFC2, CFC3, CFC4, CFC5, KRAS, MAP2K1, MAP2K2, BRAF, COSTS, HRAS
|
| Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome.
|
| Narumi Y, Aoki Y, Niihori T, Neri G, Cave H, Verloes A, Nava C, Kavamura MI, Okamoto N, Kurosawa K, Hennekam RC, Wilson LC, Gillessen-Kaesbach G, Wieczorek D, Lapunzina P, Ohashi H, Makita Y, Kondo I, Tsuchiya S, Ito E, Sameshima K, Kato K, Kure S, Matsubara Y.
|
| Am J Med Genet A 143(8):799-807. 2007
|
| 16 | CFC2, BRAF, CFC3, MAP21K1, CFC3, MAP2K2, CFC5, KRAS, COSTS, HRAS
|
| Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
|
| Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, Aoki Y, Matsubara Y, Arveiler B, Lacombe D, Pasmant E, Parfait B, Baumann C, HŽron D, Sigaudy S, Toutain A, Rio M, Goldenberg A, Leheup B, Verloes A, CavŽ H.
|
| J Med Genet 44(12):763-71. Epub 2007 Aug 17. 2007
|
| 17 | CFC2, BRAF, RAF1, MAP2K1, MAP2K2, CFC3, CFC4
|
| Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.
|
| Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA.
|
| Science 311(5765):1287-90. Epub 2006 Jan 26. 2006
|
| 18 | CFC2, BRAF, CFC3, MAP2K1, CFC4, MAP2K2, COSTS, HRAS
|
| Distinguishing Costello versus cardio-facio-cutaneous syndrome: BRAF mutations in patients with a Costello phenotype.
|
| Rauen KA.
|
| Am J Med Genet A 140(15):1681-3. No abstract available. 2006
|
| 19 | MAPK1, MAP2K1, MAP2K2
|
| Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1.
|
| Robinson FL, Whitehurst AW, Raman M, Cobb MH.
|
| J Biol Chem 277(17):14844-52. Epub 2002 Jan 31. 2002
|
| 20 | MAP2K1, MAP2K1P1, MAP2K2
|
| Chromosome mapping of the human genes encoding the MAP kinase kinase MEK1 (MAP2K1) to 15q21 and MEK2 (MAP2K2) to 7q32.
|
| Meloche S, Gopalbhai K, Beatty BG, Scherer SW, Pellerin J.
|
| Cytogenet Cell Genet 88(3-4):249-52. 2000
|
| 21 | MAP2K2
|
| Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms.
|
| Dérijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, Davis RJ.
|
| Science 267(5198):682-5. Erratum in: Science 1995 Jul 7;269(5220):17.
1995
|
| 22 | MAP2K1, MAP2K2
|
| Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2.
|
| Zheng CF, Guan KL.
|
| J Biol Chem 268(15):11435-9. 1993
|